[
  {
    "ts": "2026-02-20T00:28:09+00:00",
    "headline": "Eli Lilly (LLY) Announces Positive Phase 3b Results for Taltz and Zepbound Combination Treatment in Psoriasis and Obesity",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which found that using Taltz (ixekizumab) and Zepbound (tirzepatide) together provided superior results for adults with moderate-to-severe plaque psoriasis and obesity. […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-announces-positive-002809244.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "106d8d8d-bb6c-37e3-a648-bcbd7377fc4b",
      "content": {
        "id": "106d8d8d-bb6c-37e3-a648-bcbd7377fc4b",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Announces Positive Phase 3b Results for Taltz and Zepbound Combination Treatment in Psoriasis and Obesity",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which found that using Taltz (ixekizumab) and Zepbound (tirzepatide) together provided superior results for adults with moderate-to-severe plaque psoriasis and obesity. […]",
        "pubDate": "2026-02-20T00:28:09Z",
        "displayTime": "2026-02-20T00:28:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c4d6e67b238021e11470dc9116e24905",
          "originalWidth": 1920,
          "originalHeight": 1244,
          "caption": "Eli Lilly (LLY) Announces Positive Phase 3b Results for Taltz and Zepbound Combination Treatment in Psoriasis and Obesity",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SElMqZumM87KuF4X4aG9IQ--~B/aD0xMjQ0O3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/c4d6e67b238021e11470dc9116e24905.cf.webp",
              "width": 1920,
              "height": 1244,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/htNoxaL_CZnOpzUKqduTEw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c4d6e67b238021e11470dc9116e24905.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-announces-positive-002809244.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-announces-positive-002809244.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-20T05:22:22+00:00",
    "headline": "ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing",
    "summary": "Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.",
    "url": "https://www.fool.com/coverage/filings/2026/02/20/orbimed-advisors-trims-usd125-million-terns-stake-after-a-breakout-year-according-to-sec-filing/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e74420a9-6eb8-3d0c-9287-02b6a3a0af9a",
      "content": {
        "id": "e74420a9-6eb8-3d0c-9287-02b6a3a0af9a",
        "contentType": "STORY",
        "title": "ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing",
        "description": "",
        "summary": "Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.",
        "pubDate": "2026-02-20T05:22:22Z",
        "displayTime": "2026-02-20T05:22:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3fa528e68d30f5fa3b5648d68a49b954",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aTdlCNCN.XlGUNVNqBzqyQ--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3fa528e68d30f5fa3b5648d68a49b954.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4YpTbzYpiEyrBvOAscyuKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3fa528e68d30f5fa3b5648d68a49b954.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/02/20/orbimed-advisors-trims-usd125-million-terns-stake-after-a-breakout-year-according-to-sec-filing/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/orbimed-advisors-trims-125-million-052222806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TERN"
            },
            {
              "symbol": "EWTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "SVA"
            },
            {
              "symbol": "EW"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-20T05:22:22+00:00",
    "headline": "OrbiMed Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing",
    "summary": "Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.",
    "url": "https://www.fool.com/coverage/filings/2026/02/20/orbimed-advisors-trims-usd125-million-terns-stake-after-a-breakout-year-according-to-sec-filing/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e74420a9-6eb8-3d0c-9287-02b6a3a0af9a",
      "content": {
        "id": "e74420a9-6eb8-3d0c-9287-02b6a3a0af9a",
        "contentType": "STORY",
        "title": "OrbiMed Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing",
        "description": "",
        "summary": "Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.",
        "pubDate": "2026-02-20T05:22:22Z",
        "displayTime": "2026-02-20T05:22:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3fa528e68d30f5fa3b5648d68a49b954",
          "originalWidth": 384,
          "originalHeight": 384,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aTdlCNCN.XlGUNVNqBzqyQ--~B/aD0zODQ7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3fa528e68d30f5fa3b5648d68a49b954.cf.webp",
              "width": 384,
              "height": 384,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4YpTbzYpiEyrBvOAscyuKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3fa528e68d30f5fa3b5648d68a49b954.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/02/20/orbimed-advisors-trims-usd125-million-terns-stake-after-a-breakout-year-according-to-sec-filing/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/orbimed-advisors-trims-125-million-052222806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TERN"
            },
            {
              "symbol": "EWTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "SVA"
            },
            {
              "symbol": "EW"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-20T12:58:00+00:00",
    "headline": "Novo Nordisk’s Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity",
    "summary": "Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch.Exton, PA, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The obesity treatment landscape continues to evolve rapidly as demand for GLP-1–based therapies remains strong and competition intensifies. Novo Nordisk’s December 2025 FDA approval of Wegovy® (semaglutide), the first oral GLP-1 approved for chronic weight management, marked a pivotal expansion beyond injec",
    "url": "https://finance.yahoo.com/news/novo-nordisk-wegovy-pill-achieves-125800696.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "f57bf19e-813f-32b1-a2a8-a62b4e8065c8",
      "content": {
        "id": "f57bf19e-813f-32b1-a2a8-a62b4e8065c8",
        "contentType": "STORY",
        "title": "Novo Nordisk’s Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity",
        "description": "",
        "summary": "Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch.Exton, PA, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The obesity treatment landscape continues to evolve rapidly as demand for GLP-1–based therapies remains strong and competition intensifies. Novo Nordisk’s December 2025 FDA approval of Wegovy® (semaglutide), the first oral GLP-1 approved for chronic weight management, marked a pivotal expansion beyond injec",
        "pubDate": "2026-02-20T12:58:00Z",
        "displayTime": "2026-02-20T12:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/f8f458630c1e96b2642b6b17317be270",
          "originalWidth": 861,
          "originalHeight": 452,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pEzA4y5DSSGoUZ40pood2g--~B/aD00NTI7dz04NjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f8f458630c1e96b2642b6b17317be270.cf.webp",
              "width": 861,
              "height": 452,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CjS6AFRFxUBE9VKGiPrtPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f8f458630c1e96b2642b6b17317be270.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-wegovy-pill-achieves-125800696.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-wegovy-pill-achieves-125800696.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]